Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema

Phase 2 Terminated 84 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

Phase 2a multicenter, randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, efficacy, and safety of tetomilast in patients with emphysema.

Timeline

Start: 2009-03
Primary completion: 2015-07
Completion: 2015-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tetomilast	Small molecule	50 mg	Oral

Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema

Summary

Timeline

Drugs

Indications